| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785423 | Brachytherapy | 2018 | 6 Pages |
Abstract
It is possible to boost the prescription dose to the GTV-Tres achieving 140% increase, which equates to an EQD2α/β=10 > 100 Gy. Plans without both interstitial catheters and/or intrauterine within the GTV-Tres are most likely to be suboptimal. This planning study demonstrates that dose escalation to the GTV-Tres is feasible and further work into clinical application should be considered.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Niluja Thiruthaneeswaran, Nicki Groom, Gerry Lowe, Linda Bryant, Peter J. Hoskin,